Strong growth in Jazz Pharmaceuticals’┬ánarcolepsy drug Xyrem makes The Motley Fool believe the good times will continue to roll.

Xyrem is fast approaching blockbuster status, as sales grew 37% in 2014 to more than $770 million. Despite this strong growth, as of the fourth quarter of 2014 Xyrem was being used by only about 12,250 patients in the U.S., a small fraction of the 160,000 that are believed to have narcolepsy, making me believe that Xyrem looks poised for continued growth in the years ahead.

Get the full story at www.fool.com